SrasV1, PascalFrancis, Curation, bibRecord, 000164

Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary

Identifieur interne : 000164 ( PascalFrancis/Curation ); précédent : 000163; suivant : 000165

Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary

Auteurs : Alexander Bukreyev [États-Unis] ; Elaine W. Lamirande [États-Unis] ; Ursula J. Buchholz [États-Unis] ; Leatrice N. Vogel [États-Unis] ; William R. Elkins [États-Unis] ; Marisa St Claire [États-Unis] ; Brian R. Murphy [États-Unis] ; Kanta Subbarao [États-Unis] ; Peter L. Collins [États-Unis] ; A. R. Foxwell [Australie] ; A. W. Cripps [Australie]

Source :

Lancet : (British edition) [ 0140-6736 ] ; 2004.

RBID : Pascal:04-0452239

Descripteurs français

Pascal (Inist)
- Muqueuse, Prévention, Vaccination, Africain, Souche atténuée, Animal, Singe, Cercopithecus aethiops, Essai préclinique, Médecine, Homme, Immunisation, Evaluation, Syndrome respiratoire aigu sévère.
Wicri :
- topic : Vaccination, Singe, Médecine, Homme.

English descriptors

KwdEn :
- African, Animal, Attenuated strain, Cercopithecus aethiops, Evaluation, Human, Immunization, Medicine, Monkey, Mucosa, Preclinical trial, Prevention, Severe acute respiratory syndrome, Vaccination.

Abstract

Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease. Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.

A01	`01`	`1`		`@0 0140-6736`
A02	`01`			`@0 LANCAO`
A03		`1`		`@0 Lancet : (Br. ed.)`
A05				`@2 363`
A06				`@2 9427`
A08	`01`	`1`	`ENG`	`@1 Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary`
A11	`01`	`1`		`@1 BUKREYEV (Alexander)`
A11	`02`	`1`		`@1 LAMIRANDE (Elaine W.)`
A11	`03`	`1`		`@1 BUCHHOLZ (Ursula J.)`
A11	`04`	`1`		`@1 VOGEL (Leatrice N.)`
A11	`05`	`1`		`@1 ELKINS (William R.)`
A11	`06`	`1`		`@1 ST CLAIRE (Marisa)`
A11	`07`	`1`		`@1 MURPHY (Brian R.)`
A11	`08`	`1`		`@1 SUBBARAO (Kanta)`
A11	`09`	`1`		`@1 COLLINS (Peter L.)`
A11	`10`	`1`		`@1 FOXWELL (A. R.) @9 comment.`
A11	`11`	`1`		`@1 CRIPPS (A. W.) @9 comment.`
A14	`01`			`@1 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health @2 Bethesda, MD, 20892 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 Bioqual @2 Rockville, MD, 20850 @3 USA @Z 6 aut.`
A14	`03`			`@1 Gadi Research Centre for Medical and Health Sciences, University of Canberra @2 Canberra, ACT 2601 @3 AUS @Z 10 aut.`
A14	`04`			`@1 School of Medicine, Griffith University, Gold Coast Campus @2 Gold Coast, Queensland @3 AUS @Z 11 aut.`
A20				`@2 2102-2103,2122-2127 [8 p.]`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5004 @5 354000110516130030`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 29 ref.`
A47	`01`	`1`		`@0 04-0452239`
A60				`@1 P @3 AR @3 CT`
A61				`@0 A`
A64	`01`	`1`		`@0 Lancet : (British edition)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease. Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.
C02	`01`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Muqueuse @5 02`
C03	`01`	`X`	`ENG`	`@0 Mucosa @5 02`
C03	`01`	`X`	`SPA`	`@0 Mucosa @5 02`
C03	`02`	`X`	`FRE`	`@0 Prévention @5 03`
C03	`02`	`X`	`ENG`	`@0 Prevention @5 03`
C03	`02`	`X`	`SPA`	`@0 Prevención @5 03`
C03	`03`	`X`	`FRE`	`@0 Vaccination @5 05`
C03	`03`	`X`	`ENG`	`@0 Vaccination @5 05`
C03	`03`	`X`	`SPA`	`@0 Vacunación @5 05`
C03	`04`	`X`	`FRE`	`@0 Africain @5 06`
C03	`04`	`X`	`ENG`	`@0 African @5 06`
C03	`04`	`X`	`SPA`	`@0 Africano @5 06`
C03	`05`	`X`	`FRE`	`@0 Souche atténuée @5 08`
C03	`05`	`X`	`ENG`	`@0 Attenuated strain @5 08`
C03	`05`	`X`	`SPA`	`@0 Cepa atenuada @5 08`
C03	`06`	`X`	`FRE`	`@0 Animal @5 09`
C03	`06`	`X`	`ENG`	`@0 Animal @5 09`
C03	`06`	`X`	`SPA`	`@0 Animal @5 09`
C03	`07`	`X`	`FRE`	`@0 Singe @5 11`
C03	`07`	`X`	`ENG`	`@0 Monkey @5 11`
C03	`07`	`X`	`SPA`	`@0 Mono @5 11`
C03	`08`	`X`	`FRE`	`@0 Cercopithecus aethiops @2 NS @5 12`
C03	`08`	`X`	`ENG`	`@0 Cercopithecus aethiops @2 NS @5 12`
C03	`08`	`X`	`SPA`	`@0 Cercopithecus aethiops @2 NS @5 12`
C03	`09`	`X`	`FRE`	`@0 Essai préclinique @5 17`
C03	`09`	`X`	`ENG`	`@0 Preclinical trial @5 17`
C03	`09`	`X`	`SPA`	`@0 Ensayo preclínico @5 17`
C03	`10`	`X`	`FRE`	`@0 Médecine @5 19`
C03	`10`	`X`	`ENG`	`@0 Medicine @5 19`
C03	`10`	`X`	`SPA`	`@0 Medicina @5 19`
C03	`11`	`X`	`FRE`	`@0 Homme @5 20`
C03	`11`	`X`	`ENG`	`@0 Human @5 20`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`12`	`X`	`FRE`	`@0 Immunisation @5 23`
C03	`12`	`X`	`ENG`	`@0 Immunization @5 23`
C03	`12`	`X`	`SPA`	`@0 Inmunización @5 23`
C03	`13`	`X`	`FRE`	`@0 Evaluation @5 24`
C03	`13`	`X`	`ENG`	`@0 Evaluation @5 24`
C03	`13`	`X`	`SPA`	`@0 Evaluación @5 24`
C03	`14`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @4 CD @5 96`
C03	`14`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @4 CD @5 96`
C03	`14`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Primates @2 NS`
C07	`01`	`X`	`ENG`	`@0 Primates @2 NS`
C07	`01`	`X`	`SPA`	`@0 Primates @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Simioidea @2 NS`
C07	`04`	`X`	`ENG`	`@0 Simioidea @2 NS`
C07	`04`	`X`	`SPA`	`@0 Simioidea @2 NS`
C07	`05`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Poumon pathologie @5 38`
C07	`06`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Pulmón patología @5 38`
C07	`07`	`X`	`FRE`	`@0 Virose @2 NM @5 39`
C07	`07`	`X`	`ENG`	`@0 Viral disease @2 NM @5 39`
C07	`07`	`X`	`SPA`	`@0 Virosis @2 NM @5 39`
C07	`08`	`X`	`FRE`	`@0 Infection @2 NM`
C07	`08`	`X`	`ENG`	`@0 Infection @2 NM`
C07	`08`	`X`	`SPA`	`@0 Infección @2 NM`
N21				`@1 257`
N44	`01`			`@1 PSI`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000826

Links to Exploration step

Pascal:04-0452239

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary</title>
<author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W." last="Lamirande">Elaine W. Lamirande</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Buchholz, Ursula J" sort="Buchholz, Ursula J" uniqKey="Buchholz U" first="Ursula J." last="Buchholz">Ursula J. Buchholz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N." last="Vogel">Leatrice N. Vogel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Elkins, William R" sort="Elkins, William R" uniqKey="Elkins W" first="William R." last="Elkins">William R. Elkins</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="St Claire, Marisa" sort="St Claire, Marisa" uniqKey="St Claire M" first="Marisa" last="St Claire">Marisa St Claire</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Bioqual</s1>
<s2>Rockville, MD, 20850</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L." last="Collins">Peter L. Collins</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Foxwell, A R" sort="Foxwell, A R" uniqKey="Foxwell A" first="A. R." last="Foxwell">A. R. Foxwell</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gadi Research Centre for Medical and Health Sciences, University of Canberra</s1>
<s2>Canberra, ACT 2601</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Cripps, A W" sort="Cripps, A W" uniqKey="Cripps A" first="A. W." last="Cripps">A. W. Cripps</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>School of Medicine, Griffith University, Gold Coast Campus</s1>
<s2>Gold Coast, Queensland</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0452239</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0452239 INIST</idno>
<idno type="RBID">Pascal:04-0452239</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000826</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000164</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary</title>
<author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W." last="Lamirande">Elaine W. Lamirande</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Buchholz, Ursula J" sort="Buchholz, Ursula J" uniqKey="Buchholz U" first="Ursula J." last="Buchholz">Ursula J. Buchholz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N." last="Vogel">Leatrice N. Vogel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Elkins, William R" sort="Elkins, William R" uniqKey="Elkins W" first="William R." last="Elkins">William R. Elkins</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="St Claire, Marisa" sort="St Claire, Marisa" uniqKey="St Claire M" first="Marisa" last="St Claire">Marisa St Claire</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Bioqual</s1>
<s2>Rockville, MD, 20850</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L." last="Collins">Peter L. Collins</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Foxwell, A R" sort="Foxwell, A R" uniqKey="Foxwell A" first="A. R." last="Foxwell">A. R. Foxwell</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gadi Research Centre for Medical and Health Sciences, University of Canberra</s1>
<s2>Canberra, ACT 2601</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Cripps, A W" sort="Cripps, A W" uniqKey="Cripps A" first="A. W." last="Cripps">A. W. Cripps</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>School of Medicine, Griffith University, Gold Coast Campus</s1>
<s2>Gold Coast, Queensland</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lancet : (British edition)</title>
<title level="j" type="abbreviated">Lancet : (Br. ed.)</title>
<idno type="ISSN">0140-6736</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lancet : (British edition)</title>
<title level="j" type="abbreviated">Lancet : (Br. ed.)</title>
<idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African</term>
<term>Animal</term>
<term>Attenuated strain</term>
<term>Cercopithecus aethiops</term>
<term>Evaluation</term>
<term>Human</term>
<term>Immunization</term>
<term>Medicine</term>
<term>Monkey</term>
<term>Mucosa</term>
<term>Preclinical trial</term>
<term>Prevention</term>
<term>Severe acute respiratory syndrome</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Muqueuse</term>
<term>Prévention</term>
<term>Vaccination</term>
<term>Africain</term>
<term>Souche atténuée</term>
<term>Animal</term>
<term>Singe</term>
<term>Cercopithecus aethiops</term>
<term>Essai préclinique</term>
<term>Médecine</term>
<term>Homme</term>
<term>Immunisation</term>
<term>Evaluation</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccination</term>
<term>Singe</term>
<term>Médecine</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease. Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0140-6736</s0>
</fA01>
<fA02 i1="01"><s0>LANCAO</s0>
</fA02>
<fA03 i2="1"><s0>Lancet : (Br. ed.)</s0>
</fA03>
<fA05><s2>363</s2>
</fA05>
<fA06><s2>9427</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BUKREYEV (Alexander)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LAMIRANDE (Elaine W.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BUCHHOLZ (Ursula J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VOGEL (Leatrice N.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ELKINS (William R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ST CLAIRE (Marisa)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MURPHY (Brian R.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SUBBARAO (Kanta)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>COLLINS (Peter L.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>FOXWELL (A. R.)</s1>
<s9>comment.</s9>
</fA11>
<fA11 i1="11" i2="1"><s1>CRIPPS (A. W.)</s1>
<s9>comment.</s9>
</fA11>
<fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD, 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Bioqual</s1>
<s2>Rockville, MD, 20850</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Gadi Research Centre for Medical and Health Sciences, University of Canberra</s1>
<s2>Canberra, ACT 2601</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>School of Medicine, Griffith University, Gold Coast Campus</s1>
<s2>Gold Coast, Queensland</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s2>2102-2103,2122-2127 [8 p.]</s2>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5004</s2>
<s5>354000110516130030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0452239</s0>
</fA47>
<fA60><s1>P</s1>
<s3>AR</s3>
<s3>CT</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Lancet : (British edition)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease. Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Muqueuse</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Mucosa</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Mucosa</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Prévention</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prevention</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Prevención</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Africain</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>African</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Africano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Souche atténuée</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Attenuated strain</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cepa atenuada</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Animal</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Animal</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Animal</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Singe</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Monkey</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Mono</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cercopithecus aethiops</s0>
<s2>NS</s2>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Cercopithecus aethiops</s0>
<s2>NS</s2>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cercopithecus aethiops</s0>
<s2>NS</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Essai préclinique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Preclinical trial</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ensayo preclínico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Médecine</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Medicine</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Medicina</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Immunisation</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Immunization</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Inmunización</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Evaluation</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Evaluation</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Evaluación</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Simioidea</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Simioidea</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Simioidea</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fN21><s1>257</s1>
</fN21>
<fN44 i1="01"><s1>PSI</s1>
</fN44>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000164 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000164 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0452239
   |texte=   Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary

Mucosal immunisation of african green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Commentary

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri